香秀 asked in 社會與文化語言 · 10 years ago

拜託幫忙翻譯醫用英文摘要,急!謝謝您!!!!!

Extended-spectrum beta-lactamases (ESBLs) efficiently hydrolyze extended-spectrum beta-lactams such as cefotaxime, ceftriaxone, ceftazidime, and aztreonam. ESBLs are most often plasmid-mediated. In Taiwan, the prevalence of ESBLs in bacteria has risen, ranging from 8.5 to 29.8% in Klebsiella pneumoniae and 1.5 to 16.7% in Escherichia coli isolates. The most prevalent types of ESBLs are SHV-5, SHV-12, CTX-M-3, and CTX-M-14 in isolates of K. pneumoniae and E. coli, with differences between institutions. SHV-12 and CTX-M-3 have been reported as the most common ESBLs in isolates of Enterobacter cloacae and Serratia marcescens, respectively. Molecular epidemiology studies suggest that the ESBL-encoding genes have been disseminated either by proliferation of epidemic strains or by transfer of plasmids carrying the resistance traits. The current ESBL screen guidelines of the Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards) are issued for E. coli, Klebsiella spp., and Proteus mirabilis. Owing to the lack of standard methods, it remains difficult to assure the presence of ESBL in an isolate co-harboring an AmpC beta-lactamase, particularly in cases where the latter is produced in larger amounts than the former. Empirical therapy with piperacillin-tazobactam to replace third-generation cephalosporins may help to reduce the occurrence of ESBLs in an institution with a high prevalence of ESBL producers. Carbapenems remain the drugs of choice for serious infections caused by ESBL-producing organisms. To retard the selection for carbapenem-resistant bacteria, 7-alpha-methoxy beta-lactams or fourth-generation cephalosporins can be therapeutic alternatives for mild-to-moderate infections provided that the pharmacokinetic and pharmacodynamic target can be easily achieved

1 Answer

Rating
  • 10 years ago
    Favorite Answer

    廣譜β-內酰胺酶(ESBLs的)有效水解廣譜β-內酰胺類,如頭孢噻肟,頭孢曲松,頭孢他啶,和氨曲南。內酰胺酶是最常見的質粒介導的。在台灣,產 ESBLs細菌中普遍存在的上升,從 8.5至29.8%的肺炎克雷伯菌和16.7%,在1.5至大腸桿菌菌株。最常見的類型是SHV的產 ESBLs - 5,SHV型- 12,CTX - M型- 3和CTX - M的- 14株肺炎克雷伯菌和大腸桿菌,而不同機構之間。的SHV - 12和CTX - M - 3的一直被列為最常見的ESBLs的陰溝腸桿菌的分離和粘質沙雷氏菌,分別為。分子流行病學研究表明,內酰胺酶編碼基因已被傳播或者流行株的擴散或轉移載體的阻力特性。當前屏幕的指引內酰胺酶的臨床和實驗室標準化研究所(原國家臨床實驗室標準化委員會)發出的大腸桿菌,克雷白桿菌。,和奇異變形桿菌。由於缺乏標準的方法,它仍然難以保證在場的內酰胺酶菌株中的合作,窩藏的AmpCβ-內酰胺酶,尤其是在後者的情況下產生較大金額超過前者。經驗性治療與哌拉西林三唑巴坦替換第三代頭孢菌素,也有助於減少發生產 ESBLs的機構具有高患病率內酰胺酶生產商。碳青黴烯類藥物的選擇仍然是嚴重的感染所造成的產 ESBL生物體。為了延緩選擇碳青黴烯類耐藥細菌,7 -α-甲氧基β-內酰胺類或第四代頭孢菌素可替代治療輕度至中度感染規定,藥代動力學和藥效學的目標可以很容易地實現聆聽以拼音方式閱讀字典 - 檢視詳細字典

    Source(s): 自己
Still have questions? Get your answers by asking now.